Potential Polyvaccine Based on Microbial IgA1 Protease for Prophylaxis of Bacterial Meningitis

The immunogenic and protective activities of recombinant IgA1 serine protease obtained on the base of the genome DNA of N. meningitidis serogroup B strain H44/76 were studied. A several recombinant proteins of different molecular weights that are based on the full-length primary structure of the enzyme, taking into account the distribution of B- and T-epitopes, also were studied. In experiments on laboratory animals it was shown that a number of tested preparations demonstrate the immunogenic and protective activity to protect mice from lethal challenge with virulent strains of meningococcus serogroups A, B and C, thereby exhibiting polyvaccine properties. The protective role of antibodies against the IgA1 protease was shown when mice were infected by meningococccus serogroup B. The increase in antibodies to the meningococcal IgA1 protease into the blood of rabbits infected with different serotypes of pneumococci has been detected, indicating potential ability of the meningococcal IgA1 protease to generate protection against microbes the virulence of which is caused by IgA1protease.

менингококковая поливакцина, IgAl-протеаза, рекомбинантные белки, иммуногенность, протективность, meningococcal polyvaccine, IgA1 protease, recombinant proteins, immunogenicity, protectivity

1. Mochado P.A .In: Vaccine meningitis and rabies. Materials of Soviet-French Symposium. Moscow.1978: 52.

2. Chernysheva T.F., Favorova L.A., Krylov E.P. et al. Epidemiological effectiveness of meningococcal group A lyophilized vaccine MNIIEM. In: Acute meningitis. Epidemiology and Microbiology Research Institute them. N.F. Gamaley. 1982: 37 – 42.

3. Frasch C.E. Meningococcal vaccines: Past, present and future, in Meningococcal Disease. Ed.: К Cartwright. Chichester, John Wiley. 1995; 7: 245 – 283.

4. Sierra, G. V. G., Campa H.C., N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo et. al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. Nat. Inst. Public Health Ann. 14:195 – 207. NIPH Ann. 1991; 14: 195 – 210.

5. Platonov A.E., Harith S.M., Platonova O.V. Vaccination meningococcal disease in the world and in Russia. Epidemiologia i Vakcinoprofilaktika. [Epidemiology and Vaccinal Prevention]. 2009; 5 (48): 32 – 46.

6. Nesmeyanov V.A., Kotel’nikova O.V., Vol’pina O.M., Feoktistov K.M., Chibiskova O.V., Zhmak M.N. et al. Method of preparation of a bivalent vaccine against meningococcal infection of serogroup B/A or B/C on the basis of synthetic peptides, and without using capsular polysaccharide adjuvant. RU N2250113, 20.04.2003.

7. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G. et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012; (307): 573 – 582.

8. Kilian M., Thomsen B., Petersen T.H.E., Bleeg H. Molecular biology of Haemophilus influenzae IgA1 proteases. Mol. Immunol. 1983; 20: 1051 – 1058.

9. Mulks M.H., Kornfeld S.J., Plaut A.G. Specific proteolysis of human IgA by Streptococcus pneumoniae and Haemophilus influenzae. Journal of Infectious Diseases. 1980; 141: 450 – 456.

10. Kazeeva T.N., Shevelev A.B., Leonovich O.A, Faizov T.H., Belyakov A.V., Lebedev A.A. et al. Structural features ifunktsionalnye IgA1 proteases. Sovremennie problemi nauki i obrazovania. [Modern problems of science and education]. 2012; 1.

11. Bachovchin W.W., Plaut A.G., Flentke G.R., Lynch M., Kettner C.A. Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Haemophilus influenzae by peptide prolyl boronic acids. J. Biol. Chem. 1990; 265 (7): 3738 – 3743.

12. Alliluev A.P., Yagudaeva E.Y., Zhigis L.S., Kozlov L.V., Kotelnikova O.V., Zueva V.S. et al. A method for producing IgA1 protease from a culture of Neisseria meningitidis serogroup A and immunogenic a drug based on it. RU C1 № 2407792. 2010.

13. Rumsh L.D., Melnikov E.E., Alliluev A.P., Kozlov L., Kotelnikova O.V., Zhigis L.S. et al. Nucleic acid encoding a functionally active recombinant IgA1 protease, Neisseria meningitides serogroup B, a recombinant plasmid DNA comprising a nucleotide sequence encoding active IgA1 protease-producing strain, containing plasmid DNA, producing the mature form IgA1 protease, recombinant Ig protease of Neisseria meningitides serogroup The method for producing mature IgA1 protease shape having immunogenic and protective properties.. RU №2453599. 2012.

14. Serova O.V., Melnikov E.E., Zinchenko A.A., Kotelnikova O.V., Alliluev A.P., Bichucher A.M. et al. Recombinant IgA1 protease N. meningitidis. Getting properties. Biofarmaceftichesky Zhurnal. [Biopharmaceutical Journal]. 2011; 3 (6): 42 – 47.

15. Rumsh L.D., Serova O.V., Zinchenko A.A., Alliluev A.P., Kozlov L.V., O.V. Kotel’nikova et al. A polynucleotide encoding IgA1 protease mutant recombinant Neisseria meningitidis serogroup B, a recombinant plasmid DNA comprising the polynucleotide, host cells containing said plasmid DNA, recombinant Neisseria meningitidis IgA1 protease serogroup B, a method of producing mature IgA1 protease form. RU № 2486243. 2013.

16. Kotel’nikova O.V., Alliluev A.P., Drozhzhina E.Yu., Koroleva I.S., Sitnikova E.A., Zinchenko A.A. et. al. Protective properties of recombinant IgA1 protease from meningococcus. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2013; 7 (4): 305 – 310.

17. Kotel’nikova O.V., Zinchenko A.A., Gordeeva E.A., Melikhova T.D., Nokel E.A., Zhigis L.S. et al. Prospective use of microbial proteases secreted for the prevention of meningococcal meningitis. Collection: Clinical Medicine. Collected between materials. Scien. Conf., 3 session. Ed.: Filimonova O.I. 2015: 17 – 26.

18. Kotelnikova O.V., Zinchenko A.A., Vikhrov A.A., Alliluev A.P., Serova O.V., Gordeeva E.A. et al. Serological analysis of immunogenic properties of recombinant meningococcus Iga1 protease-based proteins. Bull. Exp. Biol. Med. 2016; 161 (3): 391 – 394.

19. Kuznetsova S.A., Kositskaya L.S., Sokolov D.I., Freidlin I.S., Polosuhina E.R., Baryshnikov A.Yu. Using the enzyme immunoassay for assessing expression of adhesion molecules on endothelial cells. Medicinskaya immunologia. [Medical Immunology]. 1999; 1 (5): 71 – 74.

20. Emini E.A., Hughes J.V., Perlow D.S., Boger J., Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 1985; 55 (3): 836 – 839. Available at: http://tools.iedb.org/bcell.

21. Combet C., Blanchet C., Geourjon C., Deléage G. NPS: network protein sequence analysis.Trends Biochem. Sci. 2000; 25: 147 – 150.

22. Zinchenko A.A., Alliluev A.P., Serova O.P., Gordeeva E.A., Zhigis L.S., Zueva V.S. et al. Immunogenic and protective properties of recombinant proteins based on meningococcal IgA1 protease. J. Meningitis. 2015. 1:102, doi: 10.4172/jomg.1000102.

23. Lomholt H., Poulsen K., Kilian M. Comparative characterization of the iga gene encoding IgA1 protease in Neisseria meningitidis. Neisseria gonorrhoeae and Haemophilus influenzae. Mol. Microbiol. 1995; 15 (3): 495 – 506.

24. Romanello V., Marcacci M., Dal Molin F., Moschioni M., Censini S., Covacci A. et al. Cloning, expression, purification, and characterization of Streptococcus pneumoniae IgA1 protease. Protein Expr. Purif. 2006; 45 (1): 142 – 149.